CANONSBURG (dpa-AFX) - French drugmaker Sanofi ( SNYNF, SNY) is said to have taken interest from private-equity firms such as KKR & Co.(KKR), Blackstone Group (BX) and TPG Capital, for the sale of its portfolio of older, off-patent drugs, according to Bloomberg.
As per Sanofi's internal document circulated by a labor union this month, the portfolio currently has an enterprise value of 6.3 billion euros or $8.5 billion, with the company still reviewing options for its mature-drug portfolio.
As part of the document, Sanofi has held discussions with Mylan Inc., (MYL) Abbott Laboratories (ABT) and firms like Warburg Pincus LLC regarding a possible sale of its mature-products portfolio in Europe. Also, the firm is said to be considering possible partnerships for the assets, the document indicates. Drug makers like Merck & Co. (MRK) and GlaxoSmithKline Plc (GSK.L, GSK) are also reviewing their portfolios of established drugs.
Copyright RTT News/dpa-AFX